Pfizer Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
Pfizer Inc. is a premier global biopharmaceutical company that discovers, develops, manufactures, and sells healthcare products, including innovative medicines and vaccines.
professionals from Deloitte
Used by professionals from
About this model
This model provides a sum-of-the-parts equity valuation and pipeline scenario analysis to determine if Pfizer's current share price accurately reflects the long-term growth potential of its Seagen oncology acquisition and internal pipeline against the impending loss of exclusivity (LOE) cliffs for key drugs like Eliquis and Ibrance.
Pfizer Inc. is a premier global biopharmaceutical company that discovers, develops, manufactures, and sells healthcare products, including innovative medicines and vaccines. The company operates a highly diversified portfolio across multiple therapeutic areas, transitioning from a period of unprecedented COVID-19 driven revenue to a focus on oncology and internal medicine.
Business segments include:
- Primary Care (approx. 45-50% of revenue): Includes internal medicine, vaccines (Prevnar family), and COVID-19 products (Comirnaty, Paxlovid).
- Specialty Care (approx. 20-25% of revenue): Includes treatments for rare diseases, inflammation, and immunology (Vyndaqel, Xeljanz).
- Oncology (approx. 20-25% of revenue): Includes legacy Pfizer oncology (Ibrance, Xtandi) and the recently acquired Seagen antibody-drug conjugate (ADC) portfolio.
- Business Innovation / PC1 (approx. 2-3% of revenue): Pfizer CentreOne contract manufacturing and active pharmaceutical ingredient sales.
Key geographies: The United States is the largest market (approx. 60% of revenue), followed by other developed markets and emerging markets (including China). Business model type: Asset-heavy manufacturing combined with highly intellectual property-driven R&D and commercialisation. Competitive position: Top 5 global pharmaceutical company by revenue, competing with Johnson & Johnson, Merck, AbbVie, and Novartis. Recent major events: Acquired Seagen for $43 billion in December 2023 to transform its oncology pipeline; executed a major cost-realignment programme targeting $4.5 billion in net cost savings by the end of 2025; experienced a massive normalisation in COVID-19 revenues resulting in significant non-cash revenue reversals in late 2023 and early 2024.
The downloadable Pfizer financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsPfizer financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $73.64B | $91.79B | $50.91B | $63.63B | $62.58B |
| Acquired in-process research and development expenses | $3.47B | $953.0M | $194.0M | $108.0M | $1.61B |
| Research and development expenses(a | $13.83B | $11.43B | $10.68B | $10.82B | $10.44B |
| Net income | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Pfizer
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Primary Care
- Segment name: Primary Care
- Revenue driver formula: (Vaccine Doses Administered x Net Price per Dose) + (Prescription Volume x Net Realised Price)
- Historical growth rate: Highly volatile due to COVID-19; non-COVID operational growth typically 3-5% CAGR.
- Key growth levers and headwinds: Prevnar 20 uptake in adult and paediatric populations; Nurtec ODT growth in migraine; headwind from the continued normalisation of Comirnaty and Paxlovid demand.
- Pricing dynamics: Heavily contracted with governments (for COVID products) and managed care organisations; subject to US Inflation Reduction Act (IRA) pricing pressures.
- Revenue recognition notes: Product sales recognised upon transfer of control; Paxlovid experienced a $3.5 billion non-cash revenue reversal in Q4 2023 due to US government returns, partially adjusted in Q1 2024.
- Seasonality: Q3 and Q4 are typically stronger due to the autumn/winter respiratory vaccination season.
Specialty Care
- Segment name: Specialty Care
- Revenue driver formula: Patient Population x Market Share x Annual Treatment Cost x Compliance Rate
- Historical growth rate: 5-8% CAGR.
- Key growth levers and headwinds: Vyndaqel family (transthyretin amyloid cardiomyopathy) is a major growth driver; headwinds from Xeljanz safety label changes and upcoming LOEs.
- Pricing dynamics: High-cost, low-volume rare disease pricing model; high reliance on patient assistance programmes and specialty pharmacy distribution.
- Revenue recognition notes: Standard gross-to-net deductions for rebates, chargebacks, and co-pay assistance.
- Seasonality: Q1 is often the weakest due to US insurance deductible resets (the "co-pay effect").
Oncology
- Segment name: Oncology
- Revenue driver formula: (Incident Patient Population x Duration of Therapy x Net Price) + Alliance Revenue (Profit Share)
- Historical growth rate: Flat to low single digits prior to Seagen; expected to grow 10%+ CAGR with Seagen integration.
- Key growth levers and headwinds: Integration and label expansion of Seagen ADCs (Padcev, Adcetris, Tukysa); severe headwind from Ibrance competitive pressures and impending LOE; Xtandi continued growth.
- Pricing dynamics: High pricing power for novel mechanisms, though combination therapies face pricing scrutiny.
- Revenue recognition notes: Includes direct product sales and alliance revenues (e.g., Xtandi profit share with Astellas).
- Seasonality: Generally not seasonal.
Business Innovation
- Segment name: Pfizer CentreOne (PC1)
- Revenue driver formula: Contracted Manufacturing Volume x Toll Rate
- Historical growth rate: 2-4% CAGR.
- Key growth levers and headwinds: Utilisation of excess manufacturing capacity; headwind from general biotech funding slowdown affecting contract development.
- Pricing dynamics: Long-term contractual pricing with raw material pass-throughs.
- Revenue recognition notes: Recognised over time as manufacturing services are rendered.
- Seasonality: Minimal seasonality; driven by client batch scheduling.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Raw materials, active pharmaceutical ingredients (API), direct manufacturing labour, overhead, royalties paid to third parties, and inventory write-offs.
- Gross margin range: 68% to 75% (Adjusted gross margin was 74% in 2024).
- Key input costs and commodity exposures: Specialised chemical precursors, biological materials, and energy costs for manufacturing facilities.
- How COGS scales with revenue: Step-function scaling based on facility utilisation; highly sensitive to product mix (e.g., alliance revenues have 100% gross margin, while manufactured products have standard COGS).
Operating Expenses
- R&D: Typically 15-18% of revenue ($10.8 billion in 2024). Covers basic research, clinical trials (Phases I-III), and regulatory submissions. Expensed as incurred unless acquired with alternative future use.
- SG&A: Typically 20-25% of revenue. Includes sales force deployment, direct-to-consumer advertising, and corporate overhead.
- Depreciation & Amortisation: Significant amortisation of intangible assets (approx. 5-7% of revenue) due to historical acquisitions (Wyeth, Hospira, Seagen).
- Stock-Based Compensation: Approx. 1-2% of revenue.
- Restructuring / one-time charges: Frequent and material. The current cost realignment programme targets $4.5 billion in savings by 2025, generating significant upfront severance and facility exit charges.
Margin Profile
- Gross margin: 70-75% (Adjusted).
- EBITDA margin: 30-35% (excluding COVID peak years).
- Operating margin: 25-30% (Adjusted).
- Net margin: 20-25% (Adjusted).
- Margin trend: Expanding post-2023 trough as COVID inventory write-offs subside and the $4.5 billion cost realignment programme flows through the P&L.
Balance Sheet Structure
- Total assets: Approx. $220-230 billion.
- Key asset categories: Identifiable intangible assets, goodwill, property, plant and equipment, and accounts receivable.
- Goodwill & intangibles as % of total assets: Very high (approx. 45-55%) following the $43 billion Seagen acquisition and previous deals (Biohaven, GBT).
- Working capital profile:
- Days Sales Outstanding (DSO): 60-70 days.
- Days Inventory Outstanding (DIO): 200-250 days (pharma manufacturing requires long lead times and safety stock).
- Days Payable Outstanding (DPO): 50-60 days.
- Net working capital as % of revenue: 15-20%.
- Is working capital positive or negative? Positive. The company requires significant inventory investment to support global supply chains.
- PP&E: Approx. $20-25 billion. Consists of global manufacturing facilities, R&D laboratories, and corporate offices. Useful lives range from 15-40 years for buildings and 5-20 years for machinery.
- Right-of-use assets / operating leases: Approx. $1.5-2.0 billion; material but not a primary driver of leverage.
Capital Expenditure & Investment
- Capex as % of revenue: 4-6% ($2.5-$3.5 billion annually).
- Maintenance capex vs. growth capex: Roughly 40% maintenance / 60% growth (capacity expansion for biologics and sterile injectables).
- Major capex programmes underway or planned: Upgrading manufacturing networks for mRNA technology and ADC manufacturing post-Seagen.
- Capitalised software / development costs: Minimal relative to physical PP&E; clinical trial costs are not capitalised.
- M&A pattern: Transformational acquirer (Seagen for $43 billion) mixed with frequent bolt-on acquisitions (Biohaven, Global Blood Therapeutics, Arena Pharmaceuticals).
- Typical acquisition multiple paid: Often 5-10x peak sales for clinical-stage or early-commercial biotech assets.
Debt & Capital Structure
- Total debt: Approx. $60-65 billion (elevated due to Seagen acquisition funding).
- Debt/EBITDA ratio: Currently elevated (approx. 4.0x); management target is to delever to 3.25x gross leverage by the end of 2025.
- Credit rating: A1 (Moody's) / A (S&P).
- Key debt instruments: Senior unsecured notes (bonds) and commercial paper for working capital.
- Maturity profile: Well-laddered, with average maturity exceeding 10 years.
- Interest rate profile: Predominantly fixed-rate bonds; weighted average cost of debt is approx. 3.5-4.5%.
- Covenants: Standard investment-grade covenants; no restrictive financial maintenance covenants.
- Share repurchase programme: Paused for 2024 to prioritise deleveraging; historical authorisation exists but will not be utilised until the 3.25x leverage target is met.
- Dividend policy: Highly committed to the dividend. 2024 dividend was $1.68 per share (approx. $9.5 billion total). Payout ratio is currently high relative to GAAP earnings but manageable on adjusted cash flows.
Cash Flow Characteristics
- Operating cash flow conversion: Typically 1.0x to 1.2x of Adjusted Net Income.
- Free cash flow margin: 15-20% of revenue in normalised years.
- Major non-cash items that bridge net income to OCF: Amortisation of intangibles (massive driver), depreciation, stock-based compensation, and deferred taxes.
- Working capital cash flow impact: Often a use of cash during product launch phases; inventory build was a major drag during the COVID scale-up and subsequent wind-down.
- Capex intensity: Moderate (4-6% of revenue), making the business highly free cash flow generative once R&D is funded.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than GAAP taxes due to R&D tax credits, foreign earnings mix, and timing of deductible intangible amortisation. Effective tax rate is typically 14-16%.
Sheet Structure
- Assumptions: Hardcoded inputs for macroeconomic drivers, tax rates, WACC, and scenario toggles.
- Product Revenue Build: Line-by-line forecasting for top 15 drugs (Comirnaty, Paxlovid, Eliquis, Prevnar, Vyndaqel, Ibrance, Xtandi, Nurtec, Padcev, Adcetris, etc.) using Volume x Price or market share mechanics.
- Segment Revenue: Aggregation of the Product Revenue Build into Primary Care, Specialty Care, Oncology, and PC1.
- Income Statement: Consolidated P&L mirroring the 10-K, including adjustments to bridge GAAP to Non-GAAP (Adjusted) earnings.
- Working Capital: Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO.
- PP&E and Intangibles: Waterfall schedules for capex, depreciation, and the heavy amortisation burden of acquired intangibles.
- Debt Schedule: Tranche-by-tranche bond maturity schedule, interest expense calculation, and commercial paper tracking.
- Cash Flow Statement: Indirect method starting from Net Income, adjusting for non-cash items, working capital changes, and capex.
- Balance Sheet: Standard balancing statement linking Assets to Liabilities and Equity.
- Valuation (DCF): Unlevered free cash flow calculation, terminal value (using Gordon Growth), and bridge to equity value per share.
- LOE & Pipeline Scenarios: Sensitivity tables showing the impact of Eliquis/Ibrance patent expiries and probability-weighted pipeline approvals.
Key Financial Relationships
- `Total Revenue = Primary Care Revenue + Specialty Care Revenue + Oncology Revenue + PC1 Revenue`
- `Primary Care Revenue = Comirnaty Revenue + Paxlovid Revenue + Prevnar Family Revenue + Eliquis Alliance Revenue + Other Primary Care`
- `Oncology Revenue = Legacy Pfizer Oncology + Seagen Portfolio Revenue`
- `Adjusted Gross Profit = Total Revenue - Adjusted Cost of Sales (excluding acquisition-related amortisation)`
- `Adjusted Operating Income = Adjusted Gross Profit - Adjusted R&D - Adjusted SG&A`
- `Reported Net Income = Adjusted Net Income - Amortisation of Intangibles - Restructuring Charges - Acquisition-related Costs`
- `Free Cash Flow = Cash from Operations - Capital Expenditures`
- `Gross Leverage Ratio = Total Debt / Adjusted EBITDA`
- `Dividend Payout = Total Dividends Paid / Adjusted Net Income`
- `Amortisation Expense = Beginning Intangible Assets x Blended Amortisation Rate (approx. 8-10% given useful lives)`
Cross-Sheet Dependencies
- The Product Revenue Build is the critical foundation; it feeds directly into the Segment Revenue sheet.
- Segment Revenue drives the top line of the Income Statement.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- Revenue and COGS from the Income Statement drive the Working Capital sheet (Accounts Receivable and Inventory).
- The Debt Schedule calculates Interest Expense, which feeds back into the Income Statement (creating a potential circularity if debt paydown is linked to cash sweeps; use a circularity breaker toggle).
- The Cash Flow Statement determines the ending cash balance and debt paydown capacity, which feed the Balance Sheet.
- The Balance Sheet must balance, serving as the ultimate mathematical check for the model.
Sign Convention
- Revenues and Assets: Entered and displayed as positive numbers.
- Expenses (COGS, R&D, SG&A): Entered as positive numbers in assumptions, but subtracted in formulas (e.g., `Gross Profit = Revenue - COGS`).
- Liabilities and Equity: Entered and displayed as positive numbers.
- Cash Flow Statement: Cash inflows are positive; cash outflows (capex, dividends, debt repayment) are negative.
- Contra-revenue (rebates, returns): Entered as positive numbers but subtracted from Gross Sales to reach Net Revenue.
Things Most Likely to Go Wrong
- COVID-19 Revenue Volatility: Paxlovid and Comirnaty revenues have swung wildly. Do not straight-line historical growth; model these as stabilising at a low baseline.
- GAAP vs. Non-GAAP Confusion: Pfizer's GAAP earnings are heavily depressed by intangible amortisation and restructuring. The model must forecast Adjusted Diluted EPS to align with management guidance and consensus.
- Alliance Revenue Margins: Eliquis and Xtandi are recorded as alliance revenues (profit shares). These drop straight to the bottom line with effectively 100% gross margin. Applying a standard corporate COGS margin to these lines will severely understate profitability.
- Seagen Integration: Historical Oncology segment data prior to 2024 does not include Seagen. Year-over-year comparisons for 2024 vs 2023 are skewed.
- LOE Cliffs: Eliquis faces loss of exclusivity later in the decade. The model must include a steep revenue drop-off (often 80-90% erosion over 2 years) for this product starting in the LOE year.
- Restructuring Add-backs: The $4.5 billion cost realignment programme will cause elevated one-time charges through 2025. These must be excluded from free cash flow proxies used for valuation.
- Share Count: Pfizer issued debt, not equity, for Seagen. Do not assume massive share dilution, but do account for standard stock-based compensation creep.
- Interest Expense Drag: The $43 billion Seagen acquisition added significant debt. Interest expense is materially higher post-2023 and must be modelled accurately based on the new debt load.
Validation Checks
- "Adjusted Gross Margin should be in the 70-75% range; flag if outside this band."
- "R&D as a % of revenue should remain between 15-18% to support the pipeline."
- "Total Debt should decrease year-over-year through 2025 as the company prioritises deleveraging to hit its 3.25x target."
- "Dividend per share must not decrease (management has a strict progressive/stable dividend policy); check that DPS is >= $1.68."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Eliquis revenue must decline by at least 50% in the first full year following its modelled loss of exclusivity."
- "Effective tax rate on Adjusted Income should be 14-16%."
- "Capex as % of revenue should run 4-6%."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Total Revenue Growth (ex-COVID) | 6.0 | % | Management guidance for operational growth excluding COVID products |
| Comirnaty Revenue (2025E) | 3.5 | $ Billions | Stabilised endemic vaccination rate assumption |
| Paxlovid Revenue (2025E) | 2.5 | $ Billions | Stabilised endemic treatment rate assumption |
| Adjusted Gross Margin | 74.0 | % | Actual 2024 adjusted gross margin |
| R&D Expense Margin | 17.0 | % | Aligns with $10.8B actual 2024 spend on $63.6B revenue |
| SG&A Expense Margin | 22.0 | % | Historical average adjusted for cost realignment savings |
| Effective Tax Rate (Adjusted) | 15.0 | % | Management guidance range |
| Days Sales Outstanding (DSO) | 65 | Days | Historical average based on AR balance |
| Days Inventory Outstanding (DIO) | 220 | Days | Historical average reflecting complex biologics supply chain |
| Days Payable Outstanding (DPO) | 55 | Days | Historical average |
| Capex as % of Revenue | 5.0 | % | Historical average |
| Dividend per Share | 1.68 | $ | Actual 2024 dividend, assumed flat/slight growth |
| Diluted Shares Outstanding | 5,703 | Millions | Actual Q4 2024 weighted average shares |
| Cost of Debt | 4.2 | % | Weighted average interest rate on outstanding bonds |
| WACC | 7.5 | % | Standard large-cap pharma discount rate |
| Terminal Growth Rate | 1.5 | % | Conservative long-term growth reflecting continuous patent cliffs |
Data Sources & Benchmarks
- SEC Filings: Pfizer Investor Relations website (investors.pfizer.com) for 10-K, 10-Q, and 8-K earnings releases.
- Key Peers for Benchmarking: Johnson & Johnson (JNJ), Merck & Co. (MRK), AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS).
- Industry Data Sources: EvaluatePharma (for consensus pipeline NPV and LOE dates), IQVIA (for monthly prescription volume data and pricing trends).
- Clinical Trial Data: ClinicalTrials.gov for tracking Pfizer's Phase III pipeline progress.
Sources
Do more with the Pfizer model
Frequently asked
What does Pfizer Inc. do?+
Pfizer Inc. is a premier global biopharmaceutical company that discovers, develops, manufactures, and sells healthcare products, including innovative medicines and vaccines. The company operates a highly diversified portfolio across multiple therapeutic areas, with a current focus on oncology and internal medicine.
What are Pfizer's primary revenue drivers?+
Pfizer's revenue is largely driven by its Primary Care segment, which includes internal medicine, vaccines like the Prevnar family, and COVID-19 products such as Comirnaty and Paxlovid. Specialty Care and Oncology segments also contribute significantly, with the recent Seagen acquisition bolstering its oncology portfolio.
What is the assumed revenue growth rate for Pfizer in the financial model?+
The provided financial model assumes a revenue growth rate of approximately 9.85% for Pfizer. This growth rate is intended to capture the long-term potential from the Seagen oncology acquisition and internal pipeline, balanced against the impact of upcoming loss of exclusivity for key drugs.
How does the financial model approach Pfizer's equity valuation?+
The financial model uses a sum-of-the-parts equity valuation and pipeline scenario analysis to assess Pfizer. Its purpose is to determine if the current share price accurately reflects the long-term growth potential from the Seagen oncology acquisition and internal pipeline, considering impending patent expirations.
Can I download an Excel financial model for Pfizer?+
Yes, an Excel financial model for Pfizer is available for download. This general corporate model provides a forecast horizon from FY2026 to FY2030 and includes key assumptions for revenue growth, margins, and capital expenditures.
What is the significance of goodwill and intangible assets on Pfizer's balance sheet?+
Goodwill and identifiable intangible assets represent a very high proportion of Pfizer's total assets, approximately 45-55%. This reflects the company's strategy as a transformational acquirer, highlighted by the $43 billion Seagen acquisition and other significant deals.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
AbbVie
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Explore more Healthcare financial model templates.
